Beijing Tiantan Biological Products Corp Ltd
SSE:600161

Watchlist Manager
Beijing Tiantan Biological Products Corp Ltd Logo
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Watchlist
Price: 21.26 CNY -3.8% Market Closed
Market Cap: 42B CNY
Have any thoughts about
Beijing Tiantan Biological Products Corp Ltd?
Write Note

Beijing Tiantan Biological Products Corp Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Tiantan Biological Products Corp Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Total Equity
ÂĄ10.3B
CAGR 3-Years
11%
CAGR 5-Years
23%
CAGR 10-Years
17%
Beigene Ltd
HKEX:6160
Total Equity
ÂĄ25.1B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Equity
ÂĄ12.7B
CAGR 3-Years
71%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Equity
ÂĄ30.7B
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
24%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Equity
ÂĄ31.5B
CAGR 3-Years
32%
CAGR 5-Years
47%
CAGR 10-Years
29%
Imeik Technology Development Co Ltd
SZSE:300896
Total Equity
ÂĄ6.3B
CAGR 3-Years
12%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Beijing Tiantan Biological Products Corp Ltd
Glance View

Market Cap
42B CNY
Industry
Biotechnology

Beijing Tiantan Biological Products Corp. Ltd. engages in the research and development, production and sale of biological products. The company is headquartered in Beijing, Beijing and currently employs 3,933 full-time employees. The Company’s primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The firm mainly distributes its products within domestic markets and to Hong Kong markets.

Intrinsic Value
26.91 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Beijing Tiantan Biological Products Corp Ltd's Total Equity?
Total Equity
10.3B CNY

Based on the financial report for Jun 30, 2024, Beijing Tiantan Biological Products Corp Ltd's Total Equity amounts to 10.3B CNY.

What is Beijing Tiantan Biological Products Corp Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
17%

Over the last year, the Total Equity growth was 11%. The average annual Total Equity growth rates for Beijing Tiantan Biological Products Corp Ltd have been 11% over the past three years , 23% over the past five years , and 17% over the past ten years .

Back to Top